Aelis Farma SA (AELIS.PA)
EUR 2.18
(2.83%)
EUR 2.18
(2.83%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 9.05 Million EUR | 137.7% |
| 2022 | 3.8 Million EUR | -58.03% |
| 2021 | 9.07 Million EUR | 698.15% |
| 2020 | 1.13 Million EUR | 12746.01% |
| 2019 | 8851.00 EUR | -77.85% |
| 2018 | 39.95 Thousand EUR | -53.25% |
| 2017 | 85.47 Thousand EUR | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 2.06 Million EUR | 0.0% |
| 2024 Q1 | 2.06 Million EUR | -38.05% |
| 2023 Q2 | 3.73 Million EUR | 30.99% |
| 2023 FY | 9.05 Million EUR | 137.7% |
| 2023 Q3 | 3.32 Million EUR | -10.86% |
| 2023 Q1 | 2.85 Million EUR | 56.71% |
| 2023 Q4 | 3.32 Million EUR | 0.0% |
| 2022 Q2 | 1.99 Million EUR | -6.37% |
| 2022 Q4 | 1.81 Million EUR | -11.55% |
| 2022 FY | 3.8 Million EUR | -58.03% |
| 2022 Q1 | 2.12 Million EUR | 77.79% |
| 2022 Q3 | 2.05 Million EUR | 3.34% |
| 2021 Q2 | 4.18 Million EUR | 0.0% |
| 2021 Q1 | 4.18 Million EUR | 1085.69% |
| 2021 FY | 9.07 Million EUR | 698.15% |
| 2021 Q4 | 1.19 Million EUR | 0.0% |
| 2021 Q3 | 1.19 Million EUR | -71.44% |
| 2020 Q2 | 215.5 Thousand EUR | 0.0% |
| 2020 Q1 | 215.5 Thousand EUR | 0.0% |
| 2020 FY | 1.13 Million EUR | 12746.01% |
| 2020 Q4 | 353 Thousand EUR | 0.0% |
| 2020 Q3 | 353 Thousand EUR | 63.81% |
| 2019 FY | 8851.00 EUR | -77.85% |
| 2018 FY | 39.95 Thousand EUR | -53.25% |
| 2017 FY | 85.47 Thousand EUR | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| ABIONYX Pharma SA | 4.64 Million EUR | -95.129% |
| ABIVAX Société Anonyme | 4.62 Million EUR | -95.932% |
| Adocia SA | 2.15 Million EUR | -321.116% |
| Biophytis S.A. | - EUR | -Infinity% |
| Advicenne S.A. | 3.15 Million EUR | -187.337% |
| genOway Société anonyme | 20.04 Million EUR | 54.835% |
| IntegraGen SA | 12.53 Million EUR | 27.784% |
| Medesis Pharma S.A. | 300.03 Thousand EUR | -2917.658% |
| Neovacs S.A. | 533.41 Thousand EUR | -1597.375% |
| NFL Biosciences SA | - EUR | -Infinity% |
| Plant Advanced Technologies SA | 1.68 Million EUR | -438.443% |
| Quantum Genomics Société Anonyme | 19.79 Thousand EUR | -45636.512% |
| Sensorion SA | 4.74 Million EUR | -90.889% |
| Theranexus Société Anonyme | 296.33 Thousand EUR | -2955.367% |
| TME Pharma N.V. | 17 Thousand EUR | -53158.824% |
| Valbiotis SA | 4.73 Million EUR | -91.295% |
| TheraVet SA | 1.07 Million EUR | -739.846% |
| Valerio Therapeutics Société anonyme | 1.8 Million EUR | -403.0% |
| argenx SE | 1.13 Billion EUR | 99.202% |
| BioSenic S.A. | 543 Thousand EUR | -1567.403% |
| Celyad Oncology SA | 102 Thousand EUR | -8776.471% |
| DBV Technologies S.A. | - EUR | -Infinity% |
| Galapagos NV | 239.72 Million EUR | 96.223% |
| Genfit S.A. | 28.56 Million EUR | 68.304% |
| GeNeuro SA | - EUR | -Infinity% |
| Hyloris Pharmaceuticals SA | 2.08 Million EUR | -333.828% |
| Innate Pharma S.A. | 51.9 Million EUR | 82.555% |
| Inventiva S.A. | 17.47 Million EUR | 48.195% |
| MaaT Pharma SA | 2.22 Million EUR | -306.373% |
| MedinCell S.A. | 9.16 Million EUR | 1.157% |
| Nanobiotix S.A. | 30.05 Million EUR | 69.878% |
| Onward Medical N.V. | 532 Thousand EUR | -1601.88% |
| Oryzon Genomics S.A. | 14.19 Million EUR | 36.202% |
| OSE Immunotherapeutics SA | 2.22 Million EUR | -306.556% |
| Oxurion NV | 263 Thousand EUR | -3342.586% |
| Pharming Group N.V. | 245.31 Million EUR | 96.309% |
| Poxel S.A. | 1.98 Million EUR | -357.042% |
| GenSight Biologics S.A. | 1.26 Million EUR | -614.601% |
| Transgene SA | 1.18 Million EUR | -664.696% |
| Financière de Tubize SA | - EUR | -Infinity% |
| UCB SA | 5.25 Billion EUR | 99.828% |
| Valneva SE | 153.71 Million EUR | 94.11% |
| Vivoryon Therapeutics N.V. | -3.62 Million EUR | 350.11% |